ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Horizon Therapeutics Public Limited Company

Horizon Therapeutics Public Limited Company (HZNP)

116.30
0.00
(0.00%)
Closed October 14 4:00PM
116.30
0.00
( 0.00% )
Pre Market: 8:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
116.30
Bid
116.31
Ask
116.30
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
116.30
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

HZNP Latest News

Monday’s Wall Street Highlights: Exxon Mobil, Bristol-Myers, Disney, Lockheed Martin, and more

US index futures are declining on Monday morning due to an unprecedented Hamas attack on Israel, raising global concerns. The value of oil increased, intensifying instability in markets...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DBGIDigital Brands Group Inc
$ 0.3587
(124.47%)
6.68M
BDSXBiodesix Inc
$ 2.37
(48.13%)
40
BNZIBanzai International Inc
$ 5.35
(44.59%)
1.06M
GRTSGritstone bio Inc
$ 0.0692
(28.15%)
41.89M
LIPOLipella Pharmaceuticals Inc
$ 0.49
(19.89%)
3.96M
LGHLWLion Group Holding Ltd
$ 0.004
(-50.62%)
29.51k
QRTEBQurate Retail Inc
$ 2.14
(-44.13%)
156
STIMNeuronetics Inc
$ 0.713
(-19.89%)
1
AMLIAmerican Lithium Corporation
$ 0.93
(-16.22%)
182.48k
LSBLakeShore Biopharma Company Ltd
$ 3.24
(-14.51%)
1
GRTSGritstone bio Inc
$ 0.0692
(28.15%)
41.89M
ZPTAZapata Computing Holdings Inc
$ 0.0921
(19.61%)
14.71M
DBGIDigital Brands Group Inc
$ 0.3587
(124.47%)
6.68M
LIPOLipella Pharmaceuticals Inc
$ 0.49
(19.89%)
3.96M
DJTTrump Media and Technology Group Corporation
$ 33.00
(10.18%)
2.11M

HZNP Discussion

View Posts
whytestocks whytestocks 4 years ago
News: $HZNP Horizon Therapeutics PLC (HZNP) Q2 2020 Earnings Call Transcript

Image source: The Motley Fool. Horizon Therapeutics PLC   (NASDAQ: HZNP) Q2 2020 Earnings Call Aug 5, 2020 , 8:00 a.m. ET Operator Continue reading

Read the whole news HZNP - Horizon Therapeutics PLC (HZNP) Q2 2020 Earnings Call Transcript
👍️0
whytestocks whytestocks 4 years ago
News: $HZNP Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,000,000 of ordinary shares in the...

In case you are interested HZNP - Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
👍️0
whytestocks whytestocks 4 years ago
News: $HZNP Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance

-- Record Second-Quarter 2020 Net Sales of $462.8 Million Increased 44 Percent; Second-Quarter 2020 GAAP Net Loss of $80.0 Million; Adjusted EBITDA of $190.7 Million -- -- Quarterly Orphan Segment Net Sales Increased 87 Percent to $379.3 Million; Now Represents More Than 80 Percent o...

Got this from HZNP - Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance
👍️0
Estoril Estoril 4 years ago
I don't know if you know what you are talking about...
👍️0
lambchops lambchops 4 years ago
Hold on to it. Good one!

LC

HZNP
👍️0
Estoril Estoril 4 years ago
You pegged this one. I'm still in for the ride. More potential to come.
👍️0
lambchops lambchops 4 years ago
Strong uptrend again after the CV-19 downdraft.

LC

HZNP
👍️0
lambchops lambchops 5 years ago
Soon to be $50/share!

LC

HZNP
👍️0
lambchops lambchops 5 years ago
This one is in a strong uptrend.

LC

HZNP
👍️0
grich1 grich1 5 years ago
Steady rising. $$$$$
👍️0
grich1 grich1 5 years ago
Trading is halted pending outcome. Company already has infrastructure in place for sales. This is just a formality. It’s a keeper.
👍️0
whytestocks whytestocks 5 years ago
News: $HZNP Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance

-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million; KRYSTEXXA ® Second-Quar...

Read the whole news Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
👍️0
jtf3 jtf3 7 years ago
Thought the earnings were good
👍️0
Cheds Cheds 7 years ago
Getting killed
👍️0
jtf3 jtf3 7 years ago
Not!
👍️0
Cheds Cheds 7 years ago
Bottom is in
👍️0
jtf3 jtf3 7 years ago
Down we go
👍️0
ClayTrader ClayTrader 7 years ago
* * $HZNP Video Chart 05-08-17 * *

Link to Video - click here to watch the technical chart video

👍️0
trendmkr trendmkr 8 years ago
Horizon Pharma Could Double Its Annual Sales Potential On This Near Term Catalyst http://marketexclusive.com/horizon-pharma-plc-nasdaqhznp-double-annual-sales-potential-near-term-catalyst/36480/?icd1
👍️0
$Money Bags$ $Money Bags$ 8 years ago
About 130 someone dumped a boatload of shares into the market. Probably paying for that acquisition.
👍️0
$Money Bags$ $Money Bags$ 8 years ago
They never fail to disappoint. Maybe eventually their growth will benefit shareholders.
👍️0
$Money Bags$ $Money Bags$ 8 years ago
Yeah, this thing makes those crazy moves on the regular. Some high fives under the table and champagne baths somewhere. Still solid play.
👍️0
ThatBobGuy ThatBobGuy 8 years ago
What News?

Wouldn't it be nice if we all could get the news that moved this stock all at the same time. Someone or some group knows something and I ain't in the loop. Then again, as my wife says, it's all rigged... so there's that.

GLTA
👍️0
$Money Bags$ $Money Bags$ 8 years ago
Boy she kicked the bucket after lunch today. Timberrrr.
👍️0
$Money Bags$ $Money Bags$ 8 years ago
This thing has been in the $30's with less prospect than it has now. We shall see.
👍️0
roger wilco roger wilco 8 years ago
Upward and Onward the chart goes!

👍️0
Peggy Peggy 8 years ago
Pop goes the weasel ... splat goes HZNP.
👍️0
doebop doebop 8 years ago
Nice pop here this morning
👍️0
roger wilco roger wilco 8 years ago
You just have to google it... the rumor is real
👍️0
SidewaysTrader SidewaysTrader 8 years ago
Hearing rumors about Horizon buying out Pernix Therapeutics. Anyone here know anything about that?
👍️0
$Money Bags$ $Money Bags$ 8 years ago
Yeah, we knew it wouldn't stay for long, but really shouldn't have been there in the first place. Even crazier that 10% of the float traded down. The oppressive pressure on the stock surely has to end eventually right? The stock really should be above $20, but seems to be lines ready to sell before then. Now we wait....again.

👍️0
Jumboo Jumboo 8 years ago
Were you saying something ?
👍️0
$Money Bags$ $Money Bags$ 8 years ago
With so little Brexit exposure, this thing is mopping the floor. What a turd.
👍️0
Jumboo Jumboo 8 years ago
Excellent consolidation
👍️0
$Money Bags$ $Money Bags$ 8 years ago
Yeah, I loaded the boat when it dropped. I was a little nervous for a bit, but the model is valid and has potential for a lot of growth.
👍️0
Jumboo Jumboo 8 years ago
21 next stop
👍️0
Jumboo Jumboo 8 years ago
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Three Additional Notices of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2% w/w
👍️0
MiamiGent MiamiGent 8 years ago
HZNP UBS Notes Several Positive Takeaways Following Horizon Pharma (HZNP) April 19, 2016 8:41 AM EDT

http://stockcharts.com/h-sc/ui?s=HZNP

Get Alerts HZNP Hot Sheet
Price: $14.52 +0.35%

Rating Summary:
12 Buy, 1 Hold, 1 Sell

UBS analyst Marc Goodman reiterated a Buy rating and $24 price target on Horizon Pharma (NASDAQ: HZNP) and offered several takeaways following investor meetings with CBO, Bob Carey.

(1) Duexis\Vimovo saw a higher level of restrictive plans than expected (additional step edits) such that gross-to-nets in 1Q moved to the 78-79% range vs expectations of 70- 75%. Horizon has been managing the business to $450-500\Rx. It will be lower in 1Q, and mgt would go lower on ASPs in return for volumes. Usually mgt assumes about a mid-single digit increase in payer control each year, but in 2016, it is seeing a step-wise change and it will be in double digits.

(2) Mgt acknowledges that HorizonCares has worked well the past 3 years, but it is always evaluating the changes needed for the primary care b-model to be successful for the next 3 years. Mgt seems more open to change than we have heard before.

(3) Upside areas include (a) Pennsaid as vols are running better than expected, (b) Krystexxa (the $70-80M guidance was a conservative assumption that didn't include any growth off the current runrate) that will have increased support moving forward (15-20 people up to 95 reps\special account managers), and (c) mgt admits there was a cushion in the original guidance.

(4) Mgt has increased focus on Pennsaid and has now made it the #1 detail for the 375 (up from 325 last year) primary care sales reps, as Pennsaid is more profitable with lower GtNs and no royalties relative to Duexis/Vimovo.

(5) M&A focus is (a) already- commercialized orphan products; (b) development-stage orphan products - mgt sounds much more focused here than it was a year ago; (c) specialty assets; and then (d) primary care assets. Mgt is seeing more activity today than before, but there is still a disconnect on value by the mgt teams at other companies.

(6) Mgt acknowledges that investors' attitudes towards leverage have changed. A year ago mgt was comfortable with its gross leverage ratio above 5x; now it would like to stay <4x.

(7) On Ravicti, Horizon has just gotten going in Canada and hired 3 reps. However, it doesn't sound like it is as focused on building out a footprint in Europe, as the economics don't seem to make sense.

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $15.04 yesterday.


👍️0
MiamiGent MiamiGent 8 years ago
HZNP 5 Stock Buys with Impressive Price-to-Cash Flow Ratios
April 19, 2016, 01:17:00 PM EDT By Zacks Equity Research, Zacks.com Comment


Shutterstock photo
"It is far better to buy a wonderful company at a fair price than a fair company at a wonderful price." - Warren Buffet.

Investment in stocks made on diligent value analysis is usually considered one of the best practices. It is always safest to look for the intrinsic value of stocks that are backed by sound fundamentals.

For an effective value investing, we would suggest considering Price to Cash Flow (or P/CF) ratio as one of the key metrics.

This metric evaluates the market price of the stock relative to the amount of cash flow that the company is generating on a per-share basis. One of the important factors that gives P/CF an upper hand is that operating cash flow adds back non-cash charges such as depreciation and amortization to net income, reflecting the true financial health of the company.

However, an investment decision solely based on P/CF metric may not fetch you the desired results. To identify stocks that are trading at a discount you should expand your search criteria and take into account price-to-book ratio, price-to-earnings ratio and price-to-sales ratio. Adding a favorable Zacks Rank and a Value Score of "A" or "B" to your search criteria should give you event better results, as they eliminate the chance of entering into a value trap.

The Bargain Hunting Strategy

The concept is that you have to target those stocks that are trading below their fair value. These stocks are actually trading at a bargain price and could fetch higher returns in the future. Let's quickly go through the parameters for selecting true value stocks before running the screen.

P/CF less than or equal to X-Industry Median remains our first parameter.

Price greater than or equal to 5: The stocks must all be trading at a minimum of $5 or higher.

Average 20-Day Volume greater than 100,000: A substantial trading volume ensures that the stock is easily tradable.

P/E using (F1) less than or equal to X-Industry Median: This parameter shortlists stocks that are trading at a discount or equal to their peers.

P/B less than or equal to X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.

P/S less than or equal to X-Industry Median: The P/S ratio determines how a stock price compares to its sales, lower the ratio the more attractive the stock.

PEG less than 1: The ratio is used to conclude a stock's value by taking the company's earnings growth into account. PEG ratio portrays a more complete picture than the P/E ratio, and a value of less than 1 indicates that stock is undervalued and investors need to pay less for a stock that has robust earnings growth prospect.

Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.

Value Score of less than or equal to B: Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank #1 or 2 offer the best upside potential.

Here are five of the 12 stocks that qualified the screening:

Ascena Retail Group Inc. (ASNA)

Kirkland's Inc. (KIRK)

HomeStreet, Inc. (HMST)

Hersha Hospitality Trust (HT)

Horizon Pharma plc (HZNP)


Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks' portfolios and strategies are available at: zacks.com

👍️0
MiamiGent MiamiGent 8 years ago
Short covering augmenting the continuing recovery...
👍️0
MiamiGent MiamiGent 8 years ago
HZNP Thomson Reuters/Verus upgrades HORIZON PHARMA PLC from HOLD to BUY.
BY Investars Analyst Actions - public
— 12:09 PM ET 04/18/2016
👍️0
Jumboo Jumboo 8 years ago
16.50 next stop
👍️0
MiamiGent MiamiGent 9 years ago
This was/is a safe play to stack for out sized profits.

Lot of up left, me thinks
👍️0
MiamiGent MiamiGent 9 years ago
I was ready and it's steady Eddy!

Would love to stay and watch the $$ printing machine but I's got work to do

Now you just continue on up, HZNP and I'll see you EOD.
👍️0
doebop doebop 9 years ago
Easy money back to 15
👍️0
MiamiGent MiamiGent 9 years ago
HZNP Chugging back up this morning.
Ridiculous drop yesterday, imo
Co reiterated guidance
Trade not appreciating numbers will almost always be higher in back end for juggernauts.
Easy peasy, me thinks
👍️0
Jumboo Jumboo 9 years ago
So where's the horizon now
👍️0
Jumpinjackas Jumpinjackas 9 years ago
Lucky
👍️0
sorkin sorkin 9 years ago
Sold 14.96. Lowered guidance not got for traders
👍️0
Jumpinjackas Jumpinjackas 9 years ago
Lowered guidance. It always bounces back
👍️0

Your Recent History

Delayed Upgrade Clock